Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting
Marwa N. Rahimiab,
Jo-Anne Pinsonab,
Joseph Hilton-Proctorab,
Jessica Van Zuylekombc,
Benjamin Blythbc,
Peter D. Roseltab and
Mohammad B. Haskali*ab
aDepartment of Radiopharmaceutical Sciences, Cancer Imaging, The Peter MacCallum Cancer Centre, Victoria 3000, Australia. E-mail: mo.haskali@petermac.org
bSir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria 3010, Australia
cModels of Cancer Translational Research Centre, The Peter MacCallum Cancer Centre, Victoria 3000, Australia
First published on 12th February 2026
Abstract
Correction for ‘Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting’ by Marwa N. Rahimi et al., RSC Adv., 2026, 16, 2123–2132, https://doi.org/10.1039/D5RA08789A.
The authors regret that chemical structures in Fig. 1 were incorrectly shown in the original article. The amended Fig. 1 is shown below with N-methylation of the C-terminal naphthylalanine residue for structures GA4 and GA13.
 | ||
| Fig. 1 Chemical structures of CCK2R targeting peptides CP04, GA4, and GA13. | ||
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2026 |